CLASS II ONGOING Device recall · Reported 20 Jun 2018 · FDA Enforcement Report

CellaVision DM recalled by Cellavision AB

Cellavision AB is recalling CellaVision DM, distributed nationwide in the US. The recall was initiated on 4 Dec 2017 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesVersions 6.0.1 or 6.0.2
Quantity recalledInstruments: 224 Software: 99 (US)

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-2184-2018
FDA event ID
80137
Recalling firm
Cellavision AB, Lund, N/A
Classification
Class II
Status
Ongoing
Recall initiated
4 Dec 2017
FDA classified
13 Jun 2018
Reported
20 Jun 2018
Type
Voluntary: Firm initiated
Customers notified by
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Reason category
Device Malfunction
Device type
Medical Software

Timeline

4 Dec 2017Recall initiated by company
13 Jun 2018Classified by FDA+191 days
20 Jun 2018Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

A software malfunction was found where WBC, RBC and PLT comments added after a slide is signed, are not sent to the LIS. This can only occur where customers process multiple slides per blood sample.

Device recalls are issued when a component, software or design fault could cause the device to fail or give wrong readings. Many are corrections applied in the field rather than physical returns.

Product as listed by the FDA

CellaVision DM Software versions 6.0.1 or 6.0.2 installed on the following products: CellaVision DM96, DM1200, DM9600 and DI-60 Product Usage: The devices are automated cell-locating devices. The devices automatically locates and presents images of blood cells on peripheral blood smears. The operator identifies and verifies the suggested classification of each cell according to type. The devices are intended to be used by skilled operators, trained in the use of the device and in recognition of blood cells

Where it was distributed

US Nationwide in the states of FL, IL, NY, and NC

Nationwide FloridaIllinoisNorth CarolinaNew York

Questions about this recall

Is CellaVision DM recalled?

Yes. Cellavision AB recalled CellaVision DM on 4 Dec 2017. The recall is Class II and its status is Ongoing. Recall number Z-2184-2018.

Why was it recalled?

A software malfunction was found where WBC, RBC and PLT comments added after a slide is signed, are not sent to the LIS. This can only occur where customers process multiple slides per blood sample.

Which lots are affected?

Versions 6.0.1 or 6.0.2

Where was it sold?

US Nationwide in the states of FL, IL, NY, and NC

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Cellavision AB

All 2
ReportedClassRecallCompanyReasonWhere
DeviceCLASS IIREF: CC286297 or BS737162 Automated Digital Cell Morphology analyzer recalledCellavision ABOtherNationwide

Other Medical Software recalls

All 903